What Surface Protein Do CAR T-cell Therapies Target in Lymphoma?
Lymphoma CAR T-cell therapies target CD19. This is a protein present on the surface of cells of most B-cell lymphomas. Other potential targets for future CAR T-cell therapy are under investigation and may be available to you as part of a clinical trial.
|
CAR T-cell therapy |
Brand name (Company) |
Lymphoma type(s) approved for |
Targeted protein
Axicabtagene ciloleucel
Yescarta (Kite/Gilead)
Large B-cell lymphoma, follicular lymphoma
CD19
Brexucabtagene autoleucel
Tecartus (Kite/Gilead)
Mantle cell lymphoma
CD19
Lisocabtagene maraleucel
Breyanzi (Juno Therapeutics/Bristol Myers Squibb)
Large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, small lymphocytic lymphoma
CD19
Tisagenlecleucel
Kymriah (Novartis)
Large B-cell lymphoma, follicular lymphoma
CD19